- Abou-Alfa, Ghassan K. , Geyer, Susan M. , Nixon, Andrew B. ... - - Cancer Res Commun - 2024
- Manuscript - Secondary - Primary - GI - CALGB-80802
A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.
There are 2543 items
Depth of PSA Nadir and Subsequent PSA Progression-Free Survival in Patients (pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO study (AFT-19)
Updated Progression-Free Survival from PRESTO: a Phase 3 Randomized Study of Androgen Annihilation for High-Risk Biochemically Relapsed Prostate Cancer (AFT-19)
PRESTO: A Phase III, Open-Label Study of Intensification of Androgen Blockade in Patients With High-Risk Biochemically Relapsed Castration-Sensitive Prostate Cancer (AFT-19).
Baseline Characteristics Associated with PSA Progression-Free Survival in Patients (pts) with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO study (AFT-19)
The impact of drug-drug interactions between palbociclib and proton pump inhibitors on clinical outcomes of patients with hormone receptor positive, HER2-negative, early breast cancer: an exploratory analysis of the PALLAS study
Symptom monitoring with electronic patient-reported outcomes during treatment for metastatic cancer: Survival and hospitalization results from the PRO-TECT trial (Alliance AFT-39)
TCR Sequencing to Identify Responders in Patients with Stage III NSCLC Treated with Atezoluzimab with Chemoradiation (AFT-16).
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of GRIFFIN (AFT-29) Among Clinically Relevant Subgroups
Health-related quality of life (HRQOL) results from PRESTO (AFT-19), a phase 3 randomized trial of intensification of androgen blockade in patients with high-risk biochemically relapsed castration sensitive prostate cancer.
Effectiveness of a Multimedia Educational Intervention to Improve Understanding of the Risks and Benefits of Palliative Chemotherapy in Patients With Advanced Cancer
The effect of disclosing life expectancy information on patients' prognostic understanding: secondary outcomes from a multicenter randomized trial of a palliative chemotherapy educational intervention.
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial.
Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC
Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (ppembro) and standard platinum-based chemotherapy (chemo) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) AFT-09 (Alliance)
The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)
Racial and Ethnic Differences in Clinical Outcomes among North American Patients with Hormone Receptor-Positive, HER2-negative, Early Breast Cancer in the PALLAS Trial (AFT-05)
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of GRIFFIN After 12-months of Maintenance Therapy (AFT-29)
Tolerability of veliparib (V) in combination with carboplatin (C)/paclitaxel (P) - based chemoradiotherapy (CRT) in subjects with stage III non-small cell lung cancer (NSCLC).
Veliparib (Vel) in Combination with Chemoradiotherapy (CRT) of Carboplatin/Paclitaxel (C/P) Plus Radiation in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) (AFT-07).
Identification of meaningful individual-level change thresholds for worsening on the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Efficacy and safety of veliparib plus carboplatin or carboplatin alone with neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized, Phase 3 trial
Effectiveness of an online decision support tool in communicating information about treatment options and related risks for ductal carcinoma in situ (DCIS) (AFT-25)
Oral Azacitidine (CC-486) Plus R-CHOP in Patients With High-Risk or Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma (AFT-08)
A phase I, open–label, multicenter trial of oral azacitidine (CC-486) plus R-CHOP in patients with high-risk, previously untreated diffuse large B-cell lymphoma, grade 3b follicular lymphoma, or transformed lymphoma (AFT-08)
Treatment exposure and discontinuation in the PALLAS trial: PALbociclib CoLlaborative Adjuvant Study of palbociclib with adjuvant endocrine therapy for HR+/HER2- early breast cancer (AFT-05)
PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
Local Recurrence Rates in Patients Receiving Modern Era Therapy (AFT-01)
The influence of anatomic stage and receptor status on first recurrence for breast cancer (AFT-01)
An End-of-study Subgroup Analysis of Black Patients From the Phase 2 GRIFFIN (AFT-29) Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM)
Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN
Trial In Progress: A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (AFT-41).
Effectiveness of an online decision support tool in communicating information about treatment options and related risks for ductal carcinoma in situ (DCIS) (AFT-25)
Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.
A Randomized Phase II Trial of Atezolizumab with or without Tiragolumab Before and After Definitive Chemoradiation for Unresectable Stage III NSCLC (AFT-57)
Daratumumab (DARA) + Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) With Transplant-eligible Newly Diagnosed Multiple MyNewly diagnosed multiple myeloma, daratumumab, autologous stem cell transplanteloma (NDMM): Final Analysis of GRIFFIN
The Comparative Effectiveness of Direct Oral Anti-Coagulants and Low Molecular Weight Heparins for Prevention of Recurrent Venous Thromboembolism in Cancer: The CANVAS Pragmatic Randomized Trial (AFT-28)
Demographic and symptom differences between cancer trial patients electing to complete weekly home patient-reported outcome measures (PROMs) via an automated phone call vs. email: Implications for implementing PROs into routine care. (AFT-39)
Using Stakeholder Engagement to Overcome Barriers to Implementing Patient-reported Outcomes (PROs) in Cancer Care Delivery: Approaches From 3 Prospective Studies.
Depth of response to daratumumab (DARA), lenalidomide, bortezomib, and dexamethasone (RVD) improves over time in patients (pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): GRIFFEN study update (AFT-29)
Interim safety analysis of a phase 2 randomized study of daratumumab (dara), lenalidomide (r), bortezomib (v), and dexamethasone (d; dara‐rvd) vs. rvd in patients (pts) with newly diagnosed multiple myeloma (mm) eligible for high‐dose therapy (hdt) and autologous stem cell transplantation (asct)
Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Efficacy and Safety Analysis of the Safety Run-in Population of GRIFFIN (AFT-29)
Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab (Dara), Bortezomib (V), Lenalidomide (R), and Dexamethasone (D; Dara‐Vrd) Vs. Vrd in Patients (Pts) with Newly Diagnosed (ND) Multiple Myeloma (MM) Eligible for High‐Dose Therapy (HDT) and Autologous Stem Cell Transplantation (ASCT)
